Janssen Biotech

Featured Drug Company Program


Janssen CarePath

877-227-3728 (877-CarePath)
www.JanssenCarePath.com

Janssen Biotech

800-526-7736
www.Janssenbiotech.com

Janssen Biotech, through Janssen CarePath, offers one source for patient support services, focused on access, affordability, and treatment support for patients who are prescribed a Janssen Biotech oncology medication. The Janssen CarePath program also includes patient information about each medication offered, as well as other patient support via the Janssen Learning Center. There are also tools available to help patients stay on track with taking and keeping up with their medication regimens.

The complete list of Janssen Biotech’s oncology and supportive care medications is provided in the Table.

Table Janssen Biotech Oncology and Supportive Care Drugs
Drug Indications Patient support programs Contact information
Darzalex
(daratumumab)
Relapsed or refractory multiple myeloma Janssen CarePath Savings Program www.carepathsavingsprogram.com/Pages/Darzalex
Johnson & Johnson Patient Assistance Foundation www.jjpaf.org/eligibility/?medication=DARZALEX%E2%84%A2
Doxil
(doxorubicin hydrochloride liposome injection)
Ovarian cancer; AIDS-related Kaposi’s sarcoma; multiple myeloma, in combination with bortezomib Janssen CarePath Savings Program www.janssencarepath.com/patient/doxil/patient-support
Johnson & Johnson Patient Assistance Foundation www.jjpaf.org/eligibility/?medication=DOXIL%C2%AE
Procrit
(epoetin alfa)
Chemotherapy-induced anemia Janssen CarePath Savings Program www.janssencarepath.com/patient/procrit/patient-support
Johnson & Johnson Patient Assistance Foundation www.jjpaf.org/eligibility/?medication=PROCRIT%C2%AE
Sylvant
(siltuximab)
Multicentric Castleman’s disease Janssen CarePath Savings Program www.janssencarepath.com/patient/sylvant/patient-support
Johnson & Johnson Patient Assistance Foundation www.jjpaf.org/eligibility/?medication=SYLVANT%C2%AE
SylvantOne Patient Rebate Program www.sylvant.com/for-patients/sylvantone-support-services
Yondelis
(trabectedin)
Unresectable or metastatic liposarcoma or leiomyosarcoma Janssen CarePath Savings Program www.janssencarepath.com/patient/yondelis/patient-support
Johnson & Johnson Patient Assistance Foundation www.jjpaf.org/eligibility/?medication=YONDELIS%C2%AE
Yondelis Education Support program www.yondelis.com/yes
Zytiga
(abiraterone acetate)
Metastatic, castration-resistant prostate cancer Janssen CarePath Savings Program www.janssencarepath.com/patient/zytiga/patient-support
Johnson & Johnson Patient Assistance Foundation www.jjpaf.org/eligibility/?medication=ZYTIGA%C2%AE

Janssen CarePath Savings Program

This program provides drug-specific reimbursement programs, patient assistance information, and resource services that facilitate patient access to medications.

The Janssen CarePath Savings Program may provide patients with a rebate for their out-of-pocket prescription costs. This program is geared toward patients who have commercial or private health insurance.

Zytiga Janssen CarePath Savings Program Card

Patients who have been prescribed Zytiga (abiraterone acetate) may be able to save on their copay, deductible, and coinsurance costs through the Janssen CarePath Savings Program.

Patients enrolled in this program will receive a Janssen CarePath Savings Program Card that qualifies them to pay $10 monthly for their prescription, up to a $12,000 annual benefit, 12 months after the card activation or after 12 doses, whichever comes first.

Johnson & Johnson Patient Assistance Foundation

Johnson & Johnson Patient Assistance Foundation is an independent, nonprofit organization that helps patients without adequate financial resources and with no prescription coverage obtain their medications. The program is drug-specific, and qualifying patients may be eligible to receive free medications for up to 12 months.

Information about the Johnson & Johnson Patient Assistance Foundation, including medications available through the foundation’s patient assistance program, is available at www.jjpaf.org.

Eligibility

Janssen CarePath Savings Program

Patients may qualify for enrollment in the Janssen CarePath Savings Program if they currently have private or commercial health insurance that will cover a portion of their medication costs. Patients participating in federally funded programs are not eligible for the savings program. Patients are directed to programs that can help them to afford their medications. Drug-specific eligibility criteria are available at www.janssencarepath.com.

Johnson & Johnson Patient Assistance Foundation

To qualify for enrollment in the Johnson & Johnson Patient Assistance Foundation, patients must:

  • Reside in the United States or its territories
  • Receive outpatient treatment from a licensed US healthcare provider
  • Lack prescription drug coverage
  • Meet drug-specific income eligibility requirements, available at www.jjpaf.org/eligibility.

Zytiga Janssen CarePath Savings Program Card

Patients may qualify for enrollment in this program if they:

  • Have been prescribed Zytiga
  • Have eligible private insurance
  • Are not enrolled in federal- or state-subsidized healthcare plans or programs.
Complete eligibility criteria are available at www.zytiga.com/coverage-and-resources/insurance-coverage.

Application & Enrollment

Janssen CarePath Savings Program

The enrollment process for this program varies by medication. To learn more about the application process for a specific drug, visit www.janssencarepath.com and select the prescribed medication from the drop-down menu.

Johnson & Johnson Patient Assistance Foundation

To enroll in the Johnson & Johnson Patient Assistance Foundation, patients and physicians must complete the Patient Assistance Program Application form (available at www.jjpaf.org/resources/jjpaf-application.pdf).

Applications, along with any required documentation, may be faxed to 888-526-5168, or mailed to the address listed on the form. The patient’s medical information, including the diagnosis (and a diagnosis code) and medication-specific information (with the dosage), must be completed. For Procrit (epoetin alfa), the hemoglobin level based on the most recent laboratory results must be included.

Zytiga Janssen CarePath Savings Program Card

Patients can enroll for or activate a Zytiga Janssen CarePath Savings Program Card at https://zytiga.janssencarepathsavings.com/Coupon/Zytiga.

Reimbursement

Information about reimbursement support programs for eligible patients is accessible through the CarePath portal (www.janssencarepath.com). Reimbursement programs are drug-specific. The reimbursement programs pertaining to Janssen’s oncology and oncology supportive care drugs are listed below.

Darzalex (daratumumab)
Information about Darzalex reimbursement programs can be found at www.darzalex.com/patient-support/cost-support or by phone at 844-553-2792.

Doxil (doxorubicin hydrochloride liposome injection)
CarePath offers Doxil-specific reimbursement support, resources, and tools for patients and providers. More information can be found at www.janssencarepath.com/patient/doxil/patient-support or by calling 800-609-1083.

Procrit (epoetin alfa)
Procrit-specific reimbursement support, resources, and tools for patients and providers are available at www.janssencarepath.com/patient/procrit/patient-support or over the phone by dialing 800-553-3851.

Sylvant (siltuximab)
For further information on the aid for Sylvant patients, visit www.janssencarepath.com/patient/sylvant/patient-support or call them at 855-299-8844.

Yondelis (trabectedin)
For patients who are prescribed infusions of Yondelis, visit www.janssencarepath.com/patient/yondelis/patient-support for more information, or call 844-966-3354.

Zytiga (abiraterone acetate)
Patients who have been prescribed Zytiga may be able to save on copays, deductibles, and coinsurance. Enrollment forms are available at www.janssencarepath.com/patient/zytiga/patient-support.

Patients who are enrolled in this program will receive the Janssen CarePath Savings Program Card that qualifies them to receive this program’s savings.